Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

(2020) Alexander M. M. Eggermont et al.   JAMA Oncology

Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand

(2020) James Randall Patrinely et al.   EUROPEAN JOURNAL OF CANCER

Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma

(2019) Henry T. Quach et al.   JAMA Oncology

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

(2019) Tawnie J Braaten et al.   ANNALS OF THE RHEUMATIC DISEASES

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis

(2019) Alexander Faje et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients

(2019) Douglas B. Johnson et al.   Cancer Immunology Research

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Immune Checkpoint Inhibitor Toxicity in 2018

(2018) Douglas B. Johnson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

(2016) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER